Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 4
Submit an article Journal homepage
418
Views
3
CrossRef citations to date
0
Altmetric
Commentary on selected articles in this issue

The Goldilocks conundrum: how much granulocyte colony-stimulating factor following autologous stem cell transplant is ‘just right’?

Kirsten HerbertHaematology Service, Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
&
David S. RitchieHaematology Service, Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaCorrespondence[email protected]
Pages 548-549 | Published online: 25 Mar 2011

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Douglas W. Sborov, Yu Kyoung Cho, Francesca Cottini, Erinn M. Hade, Misty Lamprecht, Karen Tackett, Nidhi Sharma, Nita Williams, Junan Li, Steven Devine, Ming Poi, Mitch A. Phelps & Craig C. Hofmeister. (2017) G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leukemia & Lymphoma 58:12, pages 2947-2951.
Read now
Christian Straka, Hans Salwender, Brigitte Schnabel, Michael Sandherr, Hannes Wandt, Kai Hübel, Christof Scheid, Bernd Metzner, Marcus Hentrich, Daniel Franke, Gloria Weidenegger, Mathias Freund, Orhan Sezer, Hermann Einsele, Axel Hinke & Bertold Emmerich. (2015) Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. Leukemia & Lymphoma 56:2, pages 368-376.
Read now

Articles from other publishers (1)

Amit Khot, Michael Dickinson, Kerrie Stokes, Simon Harrison, Kate Burbury, Shaun Fleming, Dominic Wall, Peter Gambell, H. Miles Prince, John F. Seymour & David Ritchie. (2013) A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia 13:1, pages 42-47.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.